,i #aahth ,,congress #ast ,session ,h4 ,r4 #cjic ,,in ,,the ,,house ,,of ,,representatives ,may #e1 #bjbc,ms4 ,hoyle of ,oregon 7for herself1 ,mr4 ,doggett1 ,mr4 ,cohen1 ,ms4 ,de,lauro1 ,mr4 ,garca of ,illinois1 ,mr4 ,grijalva1 ,ms4 ,jayapal1 ,ms4 ,kaptur1 ,mr4 ,khanna1 ,ms4 ,norton1 ,ms4 ,pingree1 ,mr4 ,pocan1 ,ms4 ,schakowsky1 ,ms4 ,stansbury1 and ,ms4 ,tokuda7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the ,secretary of ,health and ,human ,services1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,affordable ,pricing for ,taxpayer-,funded ,prescription ,drugs ,act of #bjbc4 #b4 ,reasonable price agreement 7a7 ,in general ,all ,federal agencies providing or receiving research funding1 through a grant1 contract1 cooperative agreement1 or other agreement1 shall require in such agreement1 and in any license of the rights to a patent or regulatory test data for a biomedical product or service1 that the price of any biomedical product or service developed with the benefit of such research be reasonable 7as determined by the ,secretary7 unless the ,secretary waives such reasonable price obligation under subsection 7d74 7b7 ,prohibition against charging prices higher than in other large economies with high incomes 7#a7 ,in general ,for purposes of subsection 7a71 any reasonable pricing formula shall ensure1 without prejudice to any other standards or negotiated provisions for reasonable pricing1 that residents of the ,united ,states are not charged more for the biomedical product or service involved than the reference price for countries with large economies and high incomes4 7#b7 ,reference price ,for purposes of paragraph 7#a71 the phrase reference price for countries with large economies and high incomes means-- 7,a7 the median price charged for the biomedical product or service involved in ,canada and the additional six reference countries2 or 7,b7 a modification to such price that is adopted by regulation after providing notice and the opportunity for the public to comment1 if the ,secretary determines such modification to be an appropriate and reasonable measure to protect ,united ,states residents from paying prices that are higher than prices in other countries with large economies and high incomes4 7c7 ,additional requirements 7#a7 ,in general ,in carrying out subsection 7a71 the ,secretary may promulgate by regulation additional requirements to ensure that the price for the biomedical product or service described in subsection 7a7 be reasonable4 7#b7 ,requirements ,the additional requirements under paragraph 7#a7 shall-- 7,a7 address the public interest in ensuring that publicly supported innovations for biomedical products and services have reasonable prices2 and 7,b7 take into account-- 7i7 the importance of providing robust incentives to invest in biomedical research and development2 and 7ii7 the challenges of administering agreements described in subsection 7a71 including in cases where third parties control relevant intellectual property1 know-how1 or other assets4 7#c7 ,possible mechanisms ,the additional requirements for reasonable pricing authorized by paragraph 7#a7 may include-- 7,a7 mechanisms to-- 7i7 lower prices or shorten exclusivity periods when revenues exceed targets2 7ii7 lower prices that exceed a standard of cost per health benefit achieved2 or 7iii7 lower prices that constitute significant barriers to access or fiscal burdens on patients2 or 7,b7 a combination of mechanisms listed in subparagraph 7,a7 or other mechanisms4 7d7 ,waiver 7#a7 ,in general ,the ,secretary may waive part or all of a reasonable pricing obligation under this section upon a demonstration that such a waiver is in the public interest4 ,a decision to grant such a waiver shall set out the ,secretary's finding that the waiver is in the public interest4 7#b7 ,required process ,no waiver under paragraph 7#a7 shall take effect before-- 7,a7 the public is given notice of the proposed waiver and provided a reasonable opportunity to comment in writing and at a public hearing on the proposed waiver2 and 7,b7 the ,secretary publishes an economic analysis to justify the waiver4 7e7 ,transparency 7#a7 ,reporting ,in order to evaluate additional requirements promulgated under subsection 7c71 agreements subject to subsection 7a7 shall include a requirement that the manufacturer or other companies commercializing the biomedical product or service involved report to the ,secretary in formats determined by the ,secretary-- 7,a7 the costs of each clinical trial undertaken to support the ,federal regulatory approval of the biomedical product or service involved2 7,b7 subsidies of those costs by the ,federal ,government2 and 7,c7 the annual revenues generated by the biomedical product or service involved1 by county of sale4 7#b7 ,public availability ,the ,secretary shall make all reports under paragraph 7#a7 publicly available4 7f7 ,no effect on other requirements ,the reasonable pricing requirements imposed under this section are in addition to any other requirements to limit the price of biomedical products or services1 including such requirements imposed-- 7#a7 through standards or negotiated provisions on pricing in contracts2 or 7#b7 under chapter #ah of title #ce1 ,united ,states ,code1 to make the benefits of inventions funded by the ,federal ,government available to the public on reasonable terms4 7g7 ,definitions ,in this section3 7#a7 ,the term biomedical product or service means a drug1 vaccine1 medical device1 diagnostic test1 assistive technology1 cell- or gene-based therapy1 or other technology used to provide health care4 7#b7 ,the term medical device has the meaning given to the term device in section #bja of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba74 7#c7 ,the term ,secretary means the ,secretary of ,health and ,human ,services4 7#d7 ,the term six reference countries means the six countries1 excluding ,canada1 that over the previous three calendar years-- 7,a7 are member countries of the ,organisation for ,economic ,co-operation and ,development2 7,b7 have the largest gross domestic products2 and 7,c7 have a per capita income that is at least #ej percent of the average per capita income of the ,united ,states4